CorMedix Inc (CRMD)vsVertex Pharmaceuticals Inc (VRTX)
CRMD
CorMedix Inc
$7.83
-1.70%
HEALTHCARE · Cap: $609.91M
VRTX
Vertex Pharmaceuticals Inc
$515.44
+0.17%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2623% more annual revenue ($12.59B vs $462.25M). CRMD leads profitability with a 40.5% profit margin vs 35.0%. CRMD trades at a lower P/E of 3.6x. CRMD earns a higher WallStSmart Score of 74/100 (B).
CRMD
Strong Buy74
out of 100
Grade: B
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRMD.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$515.44
$448.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 41 in profit
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 42.1%
Revenue surging 156.5% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 40.5% and operating margin at 42.1%. Revenue growth of 156.5% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CRMD
The primary concerns for CRMD are Altman Z-Score, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CRMD profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.50 — expect wider price swings.
CRMD is growing revenue faster at 156.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (74/100 vs 64/100), backed by strong 40.5% margins and 156.5% revenue growth. VRTX offers better value entry with a 46.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?